
|Articles|March 1, 2005
March FDA Pipeline
New approvals and actions in brief
Advertisement
The meningococcal (Groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra, Sanofi Pasteur) was approved for protection against meningococcal disease in adolescents and adults aged 11 to 55 years.
FDA approved mometasone (Nasonex, Schering-Plough) for the treatment of nasal polyps in patients aged 18 years and older.
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Myqorzo is now available for rare heart condition at a $108,400 annual price
2
PBM reform. It has finally happened
3
Melanoma diagnoses projected to rise in 2026
4
ACHP announces new funding to elevate patient voices in diabetes research
5























